Shots:

• Health Canada has authorized Hyrimoz on Nov 4- 2020 for marketing in Canada. Hyrimoz has been approved for use in all same indications as reference Humira- including rheumatology- gastroenterology and dermatology
• A patient support program will be available to patients treated with Hyrimoz providing guidance with reimbursement navigation- financial assistance- administrative support & education for patients
• Hyrimoz is a fully human TNF blocker. The notice of compliance has been issued for 3 SC dosage forms: 40 mg/0.8 mL & 20 mg/0.4mL in prefilled syringe- 40 mg/0.8 mL in autoinjector

 ­ Ref: GlobeNewswire | Image: PRNewswire